SHREYASKUMAR PATEL to Gastrointestinal Neoplasms
This is a "connection" page, showing publications SHREYASKUMAR PATEL has written about Gastrointestinal Neoplasms.
Connection Strength
2.790
-
An updated review of the treatment landscape for advanced gastrointestinal stromal tumors. Cancer. 2021 07 01; 127(13):2187-2195.
Score: 0.513
-
Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway. Curr Oncol Rep. 2013 Aug; 15(4):386-95.
Score: 0.299
-
Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer Chemother Pharmacol. 2013 Aug; 72(2):277-86.
Score: 0.292
-
Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance. Cancer Treat Rev. 2012 Aug; 38(5):467-72.
Score: 0.265
-
A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer. 2003 Dec 15; 98(12):2693-9.
Score: 0.154
-
Early results from randomized phase III trial of imatinib mesylate for gastrointestinal stromal tumors. Curr Oncol Rep. 2003 Jul; 5(4):273.
Score: 0.149
-
Systemic therapy for advanced soft-tissue sarcomas. Curr Oncol Rep. 2002 Jul; 4(4):299-304.
Score: 0.139
-
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
Score: 0.130
-
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001 Aug 01; 19(15):3483-9.
Score: 0.130
-
Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors. Surg Oncol. 2000 Aug; 9(2):67-70.
Score: 0.122
-
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol. 2018 06 01; 4(6):814-820.
Score: 0.105
-
An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. Curr Oncol Rep. 2016 08; 18(8):49.
Score: 0.092
-
Adjuvant chemotherapy for soft tissue sarcomas. Surg Oncol Clin N Am. 2012 Apr; 21(2):243-53.
Score: 0.067
-
Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother. 2012 Jul; 61(7):1113-24.
Score: 0.067
-
Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer. 2010 Jan 01; 116(1):184-92.
Score: 0.058
-
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007 Jan; 14(1):14-24.
Score: 0.047
-
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004 Sep 01; 64(17):5913-9.
Score: 0.040
-
Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg. 2003 Dec; 186(6):665-9.
Score: 0.038
-
Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer. 2003 Jun 01; 97(11):2848-52.
Score: 0.037
-
Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib. Curr Oncol Rep. 2002 Nov; 4(6):504-9.
Score: 0.036
-
Tumor volume as a prognostic factor for sarcomatosis. Cancer. 2002 May 01; 94(9):2441-6.
Score: 0.009